NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 917.1 DKK | +0.78% |
|
+3.84% | +31.37% |
| 09:05pm | Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says | MT |
| 04:49pm | UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
910
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.37% | 588B | |
| -2.79% | 364B | |
| +20.34% | 326B | |
| +5.52% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +11.05% | 167B | |
| -0.09% | 161B | |
| +0.89% | 124B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk, Ypsomed Conclude Long-Term Autoinjector Supply Deal
